NCT05633602 2026-04-17
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
Phase 3 Active not recruiting
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
Eastern Cooperative Oncology Group
SWOG Cancer Research Network
Korean South West Oncology Group